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factors and accounted for $186 million or 8% of 2004 Indiana
Medicaid expenditures.
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OBJECTIVES: To compare from a managed care perspective the
total direct medical costs of escitalopram (a selective serotonin
reuptake inhibitor) and venlafaxine XR (a serotonin-norepi-
nephrine reuptake inhibitor) as the ﬁrst-line therapy for major
depressive disorder (MDD). METHODS: A cost minimization
model that assumes no differences in study clinical outcomes was
developed, based on data from a randomized, double-blind, ﬁxed
dose clinical trial of escitalopram 20 mg/day (n = 98) and ven-
lafaxine XR 225 mg/day (n = 100). Ofﬁce visits required to treat
adverse events and to manage switching for patients who drop
out were modeled. Treatment costs for AEs and ofﬁce visit costs
were taken from the literature and professional opinion. Costs
for escitalopram and venlafaxine XR were assumed at average
wholesale price (AWP), discounted 20% for managed care orga-
nizations, $2.81/day (20 mg) and $3.83/day (150 mg), respec-
tively; the costs for concomitant medications were obtained from
the Red Book (2006) and drugstore.com. RESULTS: There were
statistically signiﬁcantly more dropouts due to AEs with ven-
lafaxine-XR than with escitalopram (16% and 4%, respectively;
P < 0.01). According to this cost minimization model, treatment
costs per patient with escitalopram are $227 vs. $301 with ven-
lafaxine XR. This cost saving of 25% for escitalopram was
obtained due to lower drug costs ($93 vs. $156 per patient),
lower AE costs ($14 vs. $19 per patient) and lower drug switch-
ing cost ($39 vs. $63 per patient). One-way sensitivity analysis
assuming either no AE withdrawals, or no AEs in the venlafax-
ine XR treatment arm, showed escitalopram treatment results in
cost savings of 19% and 20%, respectively. CONCLUSION:
Based on this analysis, switching 100 MDD patients treated with
venlafaxine XR to escitalopram offers costs savings to managed
care, estimated at $7475. These cost savings could be used to
treat 33 additional patients with escitalopram at an average total
cost of $227 per patient.
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OBJECTIVES: Formulary decisions by managed care organiza-
tions (MCOs) can affect choice of drug treatment for major
depressive disorder (MDD). Drugs with poor tolerability may
impact cost of treatment due to treatment withdrawal; however,
the direct costs to MCOs of withdrawal from treatment have
rarely been estimated. The objective of this study was to estimate
the opportunity costs associated with excess patient withdrawal
with duloxetine versus escitalopram treatment from an MCO
perspective. METHODS: An opportunity cost model was con-
structed to estimate the cost of treatment withdrawals from a
prospective randomized clinical trial comparing escitalopram
(10–20 mg/day, n = 137) and duloxetine (60 mg/day, n = 133).
Proportional hazard analysis of patient disposition demonstrated
a 28% excess risk of withdrawal in the duloxetine arm after 8
weeks of treatment. The model assumes that all resources used
by patients who withdraw are wasted: 30 days of initial treat-
ment drug supplies, costs of switching to another drug, and treat-
ment of AEs for withdrawn patients. The model is based on 100
patients/arm and calculates the costs associated with 28 cases of
excess withdrawals. Treatment costs for AEs were taken from
the literature and professional opinion. Duloxetine costs were
assumed at average wholesale price (AWP), discounted 20% for
MCOs: $3.84/day (60 mg); medications costs were obtained
from the Red Book (2006) and drugstore.com. RESULTS: The
total opportunity costs are approximately $9000 ($321 per with-
drawn patient): $2500, drug costs; $4400, switching costs; and
$2000, treatment costs for AEs. One-way sensitivity analyses
included accounting for three all-cause hospitalizations 
(total costs of $22,800) increased mean opportunity cost to
$1135/withdrawn patient; assuming 50% reduction in switching
costs resulted in mean opportunity costs of $242/withdrawn
patient and reducing drug supply to 15 wasted days lowered
mean opportunity costs to $275/withdrawn patient. CONCLU-
SION: Choosing treatments with excess patient withdrawals
imposes an avoidable economic burden on MCOs.
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OBJECTIVES: While controlling for relevant and possibly con-
founding variables this study examined antidepressant treatment
patterns for Florida Medicaid recipients with a diagnosis of
MDD. The objective was to identify the types of antidepressant
medication being prescribed including tricyclic antidepressants
(TCAs), selective serotonin reuptake inhibitors (SSRIs), sero-
tonin and nor-epinephrine reuptake inhibitor (SNRIs) (e.g.Ven-
lafaxine and Duloxetine) and Bupropion. Dosage patterns and
the factors that predict service use and costs among recipients of
antidepressant therapy were analyzed. METHODS: The sample
included 25,306 patients with a diagnosis of MDD who were
enrolled in the Florida Medicaid Program during FY03-05. The
research used three years of Medicaid claims data to compare
patient demographics, diagnostic characteristics, antidepressant
medication use, index dosage and service expenditure patterns 6
months prior to and one year after the index prescription event
for antidepressant medication users. RESULTS: Among those
persons diagnosed with MDD, the majority (84.5%) received
SSRIs alone or in combination with other antidepressants,
29.2% received SNRIs alone or in combination with other anti-
depressants and 15.3% received TCAs alone or in combination
with other antidepressants. A large majority (86.5%) were also
receiving prescription pain medication. Of these, more than half
were receiving prescription narcotics. Predictors of increased
service use and cost following initiation of antidepressant treat-
ment included older age, female sex, and pre-index prescription
costs. Results showed that physical health care costs increased
after switching to any antidepressant, however behavioral health
costs tended to decrease for all treated patients overtime with the
most dramatic decreases occurring in inpatient services. CON-
CLUSION: Current data on patterns, predictors and outcomes
of antidepressant medication provided to patients with MDD are
important to understand the care provided, promote optimal
clinical practice and improve quality of care.
